Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Brief Summary: This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.


Options:
A: Arm Label: Atezolizumab Plus Nab-Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Drug: Nab-Paclitaxel | Arm Label: Placebo Plus Nab-Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nab-Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Assigned to Arm(s): Atezolizumab Plus Nab-Paclitaxel | Intervention Type: DRUG; Name: Nab-Paclitaxel; Assigned to Arm(s): Atezolizumab Plus Nab-Paclitaxel, Placebo Plus Nab-Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Plus Nab-Paclitaxel
B: Arm Label: Veliparib with Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Temozolomide | Arm Label: Placebo with Carboplatin and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Carboplatin, Drug: Paclitaxel | Arm Label: Veliparib with Carboplatin and Paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Veliparib, Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel | Intervention Type: DRUG; Name: Veliparib; Assigned to Arm(s): Veliparib with Carboplatin and Paclitaxel, Veliparib with Temozolomide | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel, Veliparib with Carboplatin and Paclitaxel | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Veliparib with Temozolomide | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo with Carboplatin and Paclitaxel, Veliparib with Carboplatin and Paclitaxel
C: Arm Label: Arm G/C; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Arm Label: Arm G/C/I; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine/carboplatin, Drug: Iniparib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): Arm G/C, Arm G/C/I | Intervention Type: DRUG; Name: Iniparib; Assigned to Arm(s): Arm G/C/I
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Physician's choice chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physician's choice chemotherapy | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Physician's choice chemotherapy; Assigned to Arm(s): Physician's choice chemotherapy

Answer: A